# Hemab Therapeutics (COAG) — News

COAG · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/coag/news

## Recent headlines

- [Acciona - Wins major power transmission project to decarbonize Western Australia](https://www.ainvest.com/news/acciona-wins-major-power-transmission-project-decarbonize-western-australia-2610) — AInvest Wire, Oct 14, 2026
  Acciona has secured a significant power transmission project in Western Australia as part of broader efforts to decarbonize the region’s energy infrastructure. The company, through its consortium, has been awarded contracts to develop over 400km of transmission lines, including the installation of…
- [Hemab Therapeutics strengthens board of directors with appointment of Keli Walbert](https://www.ainvest.com/news/hemab-therapeutics-strengthens-board-directors-appointment-keli-walbert-2609) — AInvest Wire, Sep 24, 2026
- [Hemab Therapeutics - Q2 net loss $24.20 mln, or $0.80 per share](https://www.ainvest.com/news/hemab-therapeutics-q2-net-loss-24-20-mln-0-80-share-2608) — AInvest Wire, Aug 11, 2026
- [Jefferies raises target price to $47 from $39 for HEMAB Therapeutics Holdings Inc](https://www.ainvest.com/news/jefferies-raises-target-price-47-39-hemab-therapeutics-holdings-2607) — AInvest Wire, Jul 13, 2026
  Jefferies LLC has raised its price target for Hemab Therapeutics Holdings Inc (Nasdaq: COAG) to $47 from $39, reflecting updated expectations based on recent developments in the company’s clinical pipeline and market performance. Hemab, a clinical-stage biotechnology firm focused on blood…
- [Hemab Therapeutics Holdings, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $40](https://www.ainvest.com/news/hemab-therapeutics-holdings-wainwright-initiates-coverage-buy-rating-target-price-40-2606) — AInvest Wire, Jun 17, 2026
  H.C. Wainwright has initiated coverage on Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG) with a "Buy" rating and a target price of $40 per share. Hemab, a clinical-stage biotechnology company, is focused on developing novel therapies for patients with serious bleeding and thrombotic disorders,…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).